Cytokine storm is an umbrella term that describes an inflammatory syndrome characterized by elevated levels of circulating cytokines and hyperactivation of innate and/or adaptive immune cells. One type of cytokine storm is hemophagocytic lymphohistiocytosis (HLH), which can be either primary or secondary. Severe COVID-19-associated pneumonia and acute respiratory distress syndrome (ARDS) can also lead to cytokine storm/cytokine release syndrome (CS/CRS) and, more rarely, meet criteria for the diagnosis of secondary HLH. Here, we review the immunobiology of primary and secondary HLH and examine whether COVID-19-associated CS/CRS can be discriminated from non-COVID-19 secondary HLH. Finally, we review differences in immunobiology between these different entities, which may inform both clinical diagnosis and treatment of patients.
JogalekarMPVeerabathiniAGangadaranP. SARS-CoV-2 variants: a double-edged sword?Exp Biol Med2021;246:1721–6
7.
AfewerkyHK. Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Exp Biol Med2020;245:1299–307
8.
BindoliSFelicettiMSfrisoPDoriaA. The amount of cytokine-release defines different shades of Sars-Cov2 infection.Exp Biol Med2020;245:970–6
9.
ManivannanMJogalekarMPKavithaMSMaranBAVGangadaranP. A mini-review on the effects of COVID-19 on younger individuals.Exp Biol Med2021;246:293–7
10.
UpadhyayJTiwariNAnsariMN. Role of inflammatory markers in corona virus disease (COVID-19) patients: a review.Exp Biol Med2020;245:1368–75
11.
ReisnerABlackwellLSSayeedIMyersHEWaliBHeilmanSFigueroaJLuAHussainiLAndersonEJShaneALRostadCA. Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: a pilot study.Exp Biol Med. Epub ahead of print 26 September 2021. DOI: 10.1177/15353702211046835
12.
YeQWangBMaoJ. The pathogenesis and treatment of the “cytokine storm” in COVID-19.J Infect2020;80:607–13
13.
YangYShenCLiJYuanJWeiJHuangFWangFLiGLiYXingLPengLYangMCaoMZhengHWuWZouRLiDXuZWangHZhangMZhangZGaoGFJiangCLiuLLiuY. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.J Allergy Clin Immunol2020;146:119–27.e4
14.
VaninovN. In the eye of the COVID-19 cytokine storm.Nat Rev Immunol2020;20:277
15.
TangNLiDWangXSunZ. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.J Thromb Haemost2020;18:844–7
16.
FanBEChongVCLChanSSWLimGHLimKGETanGBMucheliSSKuperanPOngKH. Hematologic parameters in patients with COVID-19 infection.Am J Hematol2020;95:E131–4
17.
JogalekarMPVeerabathiniAPatelAB. COVID-19: antiviral agents and enzyme inhibitors/receptor blockers in development.Exp Biol Med2021;246:1533–40
18.
GroupRCHorbyPLimWSEmbersonJRMafhamMBellJLLinsellLStaplinNBrightlingCUstianowskiAElmahiEPrudonBGreenCFeltonTChadwickDRegeKFeganCChappellLCFaustSNJakiTJefferyKMontgomeryARowanKJuszczakEBaillieJKHaynesRLandrayMJ. Dexamethasone in hospitalized patients with covid-19.N Engl J Med2021;384:693–704
19.
HakimNNChiJOlazagastiCLiuJM. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients.Exp Biol Med2021;246:5–9
20.
WoodHJonesJHuiKMareTPiraniTGallowayJMetaxaVBenjaminRRutherfordACainSKulasekararajAG. Secondary HLH is uncommon in severe COVID-19.Br J Haematol2020;190:e283–5
21.
DimopoulosGde MastQMarkouNTheodorakopoulouMKomnosAMouktaroudiMNeteaMGSpyridopoulosTVerheggenRJHoogerwerfJLachanaAvan de VeerdonkFLGiamarellos-BourboulisEJ. Favorable anakinra responses in severe covid-19 patients with secondary hemophagocytic lymphohistiocytosis.Cell Host Microbe2020;28:117–23
LorenzGMoogPBachmannQLa RoseePSchneiderHSchleglMSpinnerCHeemannUSchmidRMAlgulHLahmerTHuberWSchmadererC. Title: cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients.Sci Rep2020;10:18277
24.
KesselCVollenbergRMasjosthusmannKHinzeCWittkowskiHDebaugniesFNagantCCorazzaFVelyFKaplanskiGGirard-Guyonvarc’hCGabayCSchmidtHFoellDTepassePR. Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers.Arthritis Rheumatol2021;73:1791–9
25.
ShahARMuzzafarTAssiRSchellingerhoutDEstrovZTamamyanGKantarjianHDaverN. Hemophagocytic lymphohistiocytosis in adults: an under recognized entity.BBA Clin2017;7:36–40
26.
La RoseeP. Treatment of hemophagocytic lymphohistiocytosis in adults.Hematology Am Soc Hematol Educ Program2015;2015:190–6
27.
HejblumGLambotteOGalicierLCoppoPMarzacCAumontCFardetL. A web-based Delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients.PLoS ONE2014;9:e94024
28.
FardetLGalicierLLambotteOMarzacCAumontCChahwanDCoppoPHejblumG. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.Arthritis Rheumatol2014;66:2613–20
29.
La RoseePHorneAHinesMvon Bahr GreenwoodTMachowiczRBerlinerNBirndtSGil-HerreraJGirschikofskyMJordanMBKumarAvan LaarJAMLachmannGNicholsKERamananAVWangYWangZJankaGHenterJI. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.Blood2019;133:2465–77
30.
CarvelliJPiperoglouCFarnarierCCVelyFMazodierKAudonnetSNitschkePBole-FeysotCBoucekineMCambonAHamidouMHarleJRde Saint BasileGKaplanskiG. Functional and genetic testing in adults with HLH do not reveal a cytotoxicity defect but rather an inflammatory profile.Blood2020;136:542–52
31.
LerkvaleekulBVilaiyukS. Macrophage activation syndrome: early diagnosis is key.Open Access Rheumatol2018;10:117–28
32.
de Saint BasileGMenascheGFischerA. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules.Nat Rev Immunol2010;10:568–79
33.
ChaturvediVMarshRAZoref-LorenzAOwsleyEChaturvediVNguyenTCGoldmanJRHenryMMGreenbergJNLadischSHermistonMLJengMNaqviAAllenCEWongHRJordanMB. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.Blood2021;137:2337–46
34.
LinHScullBPGoldbergBRAbhyankarHAEcksteinOEZinnDJLubegaJAgrusaJEl MallawaneyNGulatiNForbesLChinnIChakrabortyRVelasquezJGoldmanJBashirDLamFMuscalEHenryMMGreenbergJNLadischSHermistonMLMeyerLKJengMNaqviAMcClainKNguyenTWongHManTKJordanMBAllenCE. IFN-gamma signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.Blood Adv2021;5:3457–67
35.
CuiYXiongXRenYWangFWangCZhangY. CD163 as a valuable diagnostic and prognostic biomarker of sepsis-associated hemophagocytic lymphohistiocytosis in critically ill children.Pediatr Blood Cancer2019;66:e27909
36.
LuoHLiuDLiuWWangGChenLCaoYWeiJXiaoMLiuXHuangGWangWZhouJWangQF. Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms.Eur J Hum Genet2021;29:1312–5
37.
McGonagleDSharifKO’ReganABridgewoodC. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease.Autoimmun Rev2020;19:102537
38.
YangLXieXTuZFuJXuDZhouY. The signal pathways and treatment of cytokine storm in COVID-19.Signal Transduct Target Ther2021;6:255
39.
RovaiESAlvesTHolzhausenM. Protease-activated receptor 1 as a potential therapeutic target for COVID-19.Exp Biol Med2021;246:688–94
40.
KyriazopoulouEPoulakouGMilionisHMetallidisSAdamisGTsiakosKFragkouARaptiADamoulariCFantoniMKalomenidisIChrysosGAnghebenAKainisIAlexiouZCastelliFSerinoFSTsilikaMBakakosPNicastriETzavaraVKostisEDagnaLKoufargyrisPDimakouKSavvanisSTzatzagouGChiniMCavalliGBassettiMKatriniKKotsisVTsoukalasGSelmiCBliziotisISamarkosMDoumasMKtenaSMasgalaAPapanikolaouIKosmidouMMyrodiaDMArgyrakiACardellinoCSKoliakouKKatsigianniEIRaptiVGiannitsiotiECingolaniAMichaSAkinosoglouKLiatsis-DouvitsasOSymbardiSGatselisNMouktaroudiMIppolitoGFlorouEKotsakiANeteaMGEugen-OlsenJKyprianouMPanagopoulosPDalekosGNGiamarellos-BourboulisEJ. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.Nat Med2021;27:1752–60
41.
CaricchioRAbbateAGordeevIMengJHsuePYNeogiTArduinoRFominaDBogdanovRStepanenkoTRuiz-SecoPGonzalez-GarciaAChenYLiYWhelanSNovielloS, CAN-COVID Investigators. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial.JAMA2021;326:230–9
42.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariMValeCLGodolphinPJFisherDHigginsJPTSpigaFSavovicJTierneyJBaronGBenbenishtyJSBerryLRBromanNCavalcantiABColmanRDe BuyserSLDerdeLPGDomingoPOmarSFFernandez-CruzAFeuthTGarciaFGarcia-VicunaRGonzalez-AlvaroIGordonACHaynesRHermineOHorbyPWHorickNKKumarKLambrechtBNLandrayMJLealLLedererDJLorenziEMarietteXMerchanteNMisnanNAMohanSVNivensMCOksiJPerez-MolinaJAPizovRPorcherRPostmaSRajasuriarRRamananAVRavaudPReidPDRutgersASancho-LopezASetoTBSivapalasingam SSoinASStaplinNStoneJHStrohbehnGWSunden-CullbergJTorre-CisnerosJTsaiLWvan HoogstratenHvan MeertenTVeigaVCWesterweelPEMurthySDiazJVMarshallJCSterneJAC. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis.JAMA2021;326:499–518
43.
SalamaCHanJYauLReissWGKramerBNeidhartJDCrinerGJKaplan-LewisEBadenRPanditLCameronMLGarcia-DiazJChavezVMekebeb-ReuterMLimadeMenezesFShahRGonzalez-LaraMFAssmanBFreedmanJMohanSV. Tocilizumab in patients hospitalized with covid-19 pneumonia.N Engl J Med2021;384:20–30
44.
LomakinNVBakirovBAProtsenkoDNMazurovVIMusaevGHMoiseevaOMPasechnikESPopovVVSmolyarchukEAGordeevIGGilyarovMYFominaDSSeleznevAILinkovaYNDokukinaEAEremeevaAVPukhtinskaiaPSMorozovaMAZinkina-OrikhanAVLutckiiAA. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.Inflamm Res2021;70:1233–46
45.
NeysSFHHendriksRWCornethOBJ. Targeting Bruton’s tyrosine kinase in inflammatory and autoimmune pathologies.Front Cell Dev Biol2021;9:668131
46.
BronteVUgelSTinazziEVellaADe SanctisFCaneSBataniVTrovatoRFioreAPetrovaVHoferFBarouniRMMusiuCCaligolaSPintonLTorroniLPolatiEDonadelloKFrisoSPizzoloFIezziMFacciottiFPelicciPGRighettiDBazzoniPRampuddaMComelAMosanerWLunardiCOlivieriO. Baricitinib restrains the immune dysregulation in patients with severe COVID-19.J Clin Invest2020;130:6409–16
47.
GolettiDCantiniF. Baricitinib therapy in covid-19 pneumonia – an unmet need fulfilled.N Engl J Med2021;384:867–9
48.
CaoYWeiJZouLJiangTWangGChenLHuangLMengFHuangLWangNZhouXLuoHMaoZChenXXieJLiuJChengHZhaoJHuangGWangWZhouJ. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial.J Allergy Clin Immunol2020;146:137–46.e3
49.
GuimaraesPOQuirkDFurtadoRHMaiaLNSaraivaJFAntunesMOKalil FilhoRJuniorVMSoeiroAMTognonAPVeigaVCMartinsPAMoiaDDFSampaioBSAssisSRLSoaresRVPPianoLPACastilhoKMomessoRMonfardiniFGuimaraesHPPoncedeLeonDDulcineMPinheiroMRTGunayLMDeuringJJRizzoLVKonczTBerwangerO, STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with covid-19 pneumonia.N Engl J Med2021;385:406–15
50.
RoschewskiMLionakisMSSharmanJPRoswarskiJGoyAMonticelliMARoshonMWrzesinskiSHDesaiJVZarakasMACollenJRoseKHamdyAIzumiRWrightGWChungKKBaselgaJStaudtLMWilsonWH. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.Sci Immunol2020;5:eabd0110
